alexa Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin ifosfamide cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
Oncology

Oncology

Journal of Cancer Science & Therapy

Author(s): Tonato M, Crin L, Mosconi AM, Tonato M, Crin L, Mosconi AM

Abstract Share this page

Abstract Cisplatin-based combination chemotherapy is currently considered the most active treatment for advanced non-small cell lung cancer (NSCLC). A recent meta-analysis of eight randomized trials comparing supportive care versus supportive care plus cisplatin-based chemotherapy showed a small (10\%) but significant survival benefit at 1 year. However, there is no consensus on a specific reference regimen for NSCLC. Our previous experience comparing cisplatin/etoposide (PE) with mitomycin/ifosfamide/cisplatin (MIC) demonstrated a significantly better response rate (40\% v 23\%) and survival advantage of the three-drug MIC combination versus PE. Among the new drugs, the nucleoside analogue gemcitabine produced response rates of approximately 20\% in advanced NSCLC. In phase I/II studies, response rates as high as 54\% and median survival of up to 13 months were seen when gemcitabine was combined with cisplatin. Therefore, a phase III study was planned to evaluate the gemcitabine/cisplatin combination versus the MIC regimen. This multicenter trial is currently ongoing in Italy.
This article was published in Semin Oncol and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords